Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.

doi:10.1093/icvts/ivab283

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.

Interactive cardiovascular and thoracic surgery - 21 Feb 2022

Moriya Tetsuji, Hamaji Masatsugu, Yoshizawa Akihiko, Miyata Ryo, Noguchi Misa, Tamari Shigeyuki, Chiba Naohisa, Miyamoto Hideaki, Toyazaki Toshiya, Tanaka Satona, Yamada Yoshito, Yutaka Yojiro, Nakajima Daisuke, Ohsumi Akihiro, Menju Toshi, Date Hiroshi

Abstract excerpt

OBJECTIVES: To clarify survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) as first-line treatment for postoperative recurrence. METHODS: A retrospective chart review was performed to identify consecutive patients who received EGFR-TKIs as first-line treatment for postoperative recurrence of non-small-cell lung cancer (NSCLC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genes, erbB-1

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34652430
DOI: 10.1093/icvts/ivab283
PMCID: PMC8860430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.PMID 34652430Read ↗

Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.Semantic proximity Read ↗

EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Relative efficacies of EGFR-TKIs and immune checkpoint inhibitors for treatment of recurrent non-small cell lung cancer after surgerySemantic proximity Read ↗

Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.Semantic proximity Read ↗

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations.Semantic proximity Read ↗

Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.Semantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?Semantic proximity Read ↗

Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.